

Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action

References

1. American Cancer Society. Prostate cancer. <http://www.cancer.org/acs/groups/cid/documents/webcontent/003134-pdf.pdf>. Accessed September 6, 2017.
2. American Cancer Society. Survival rates for prostate cancer. <https://www.cancer.org/content/cancer/en/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html>. Accessed September 6, 2017.
3. Attard G, Borre M, Gurney H, et al. A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*. 2017;35(18 Suppl): Abstract 5004.
4. Badrising S, van der Noort V, van Oort IM, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. *Cancer*. 2014;120:968-975.
5. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. *Ann Oncol*. 2013;24(9):2402-2408.
6. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. *J Clin Oncol*. 2014;32(30):3436-3448.
7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*. 2014;371:424-433.
8. Bianchini D, Lorente D, Rodriguez-Vida A, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone *Eur J Cancer*. 2014;50:78-84.
9. Bishop JL, Sio A, Angeles A, et al. PD-L1 is highly expressed in enzalutamide resistant prostate cancer. *Oncotarget*. 2015; 6:234-242.
10. Bournakis E. Enzalutamide (ENZA) in heavily pretreated patients with bone metastatic castration resistant prostate cancer (mCRPC) resistant to androgen biosynthesis inhibitor (ABI) treatment- the Hellenic experience of the Name Patient Access Program (NPAP). *Eur J Cancer*. 2013;49(suppl 2):abstract 2906.
11. Cheng HH, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. *Prostate Cancer Prostatic Dis*. 2015;18:122-127.
12. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. *Eur Urol*. 2016; 69(6):992-995.
13. ClinicalTrials.gov. Enzalutamide with or without abiraterone and prednisone in treating patients with castration-resistant metastatic prostate cancer. <https://clinicaltrials.gov/ct2/show/NCT01949337>. Accessed September 6, 2017.
14. ClinicalTrials.gov. A study of atezolizumab (anti-PD-L1 antibody) in combination with enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen (IMbassador250). <https://clinicaltrials.gov/ct2/show/NCT03016312>. Accessed September 6, 2017.
15. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet*. 2010;376(9747):1147-1154.

Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action

16. De Bono JS, Hardy-Bressard AC, Kim CS, et al. Phase III non-inferiority study of cabazitaxel (C) 20 mg/m² (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). *J Clin Oncol*. 2016;34(18 Suppl):abstract 5008.
17. Fakhrejahani F, Madan RA, Dahut WL, et al. Avelumab in metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*. 2017;35(18 Suppl): Abstract 5037.
18. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*. 2012;13(10):983-992.
19. Graff JN, Alumkal JJ, Drake CG, et al. First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC). *Ann Oncol*. 2016;27(Suppl 6): Abstract 719O.
20. Hansen A, Massard C, Ott PA, et al. Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study. *Ann Oncol*. 2016;27(Suppl 6): Abstract 725PD.
21. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. *Lancet Oncol*. 2014;15:1397-1406.
22. Ileana E, Lloriot Y, Albiges L, et al. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. *J Clin Oncol*. 2012;30(Suppl):abstract 4554.
23. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363:411-422.
24. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. 2013; 499:214-218.
25. Lloriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). *Ann Oncol*. 2013;24:1807-1812.
26. Lowrance WT, Roth BJ, Kirby E, Murad MH, Cookson MS. Castration-resistant prostate cancer: AUA guideline amendment 2015. *J Urol*. 2016;195(5):1444-1452.
27. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. *N Engl J Med*. 2015; 373:1697-1708.
28. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer. Version 2.2017. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Published 2017. Accessed September 6, 2017.
29. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res*. 2008;68(11):4447-4454.
30. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. *Ann Oncol*. 2013;24:1802-1807.
31. Oh W. Sequencing of novel prostate cancer agents is a work in progress. OnLive. <http://www.onlive.com/publications/obtn/2012/december-2012/sequencing-of-novel-prostate-cancer-agents-is-a-work-in-progress/2>. Accessed September 6, 2017.
32. Parimi S, Eigel BJ, Sunderland K, et al. Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*. 2016;34(18 Suppl): Abstract 5059.
33. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*. 2013;369(3):213-223.

Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action

34. Parker C, Garcia-Vargas J, O'Bryan-Tear CG, Fang F, Vogelzang NJ. Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial. *J Clin Oncol*. 2013;31:abstract 5060.
35. Halperin EC, Perez CA, Brady LW, eds. *Principles and Practice of Radiation Oncology*. 5th ed. Lippincott Williams & Wilkins; 2007.
36. Pritchard CC, Morrissey C, Kumar A, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. *Nat Commun*. 2014; 5:4988.
37. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. *N Engl J Med*. 2016;375:443-453.
38. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015; 161(5):1215-1228.
39. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. *J Clin Oncol*. 2011;29(27):3651-3658.
40. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*. 2013;368(2):138-148.
41. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*. 2015;16(2):152-160.
42. Sartor AO, Oudard S, Sengelov L, et al. Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-year phase III study (FIRSTANA). *J Clin Oncol*. 2016;34(18 Suppl):abstract 5006.
43. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. *Urology*. 2013;81:1297-1302.
44. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*. 2012;367(13):1187-1197.
45. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. *Eur Urol*. 2014;65(1):30-36.
46. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. *Ther Adv Med Oncol*. 2014;6:167-179.
47. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. *Scand J Urol*. 2014;48(3):268-275.
48. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366:2443-2454.